What question did this study set out to answer?

Examine the pathophysiological mechanisms, cardiovascular risks, and therapeutic reversibility of left ventricular hypertrophy.

Left Ventricular Hypertrophy

View Full Paper

Ask AI

Bookmark

Design

Review

Authors

LVH signals high CV event risk warranting attention; confirms association but leaves regression outcome benefits unproven.

Examine the pathophysiological mechanisms, cardiovascular risks, and therapeutic reversibility of left ventricular hypertrophy.
Synthesized epidemiological and clinical literature evaluating left ventricular muscle mass expansion, hemodynamic stressors, and cardiovascular outcomes.
Evaluated therapeutic responses to targeted antihypertensive regimens designed to induce regression of ventricular remodeling.
Left ventricular hypertrophy is associated with a 6- to 8-fold increase in the risk of acute myocardial infarction, congestive heart failure, and sudden cardiac death.
Pathophysiological alterations include diminished coronary flow reserve, elevated myocardial oxygen demand, ventricular ectopy, and impaired ventricular filling and contractility.
Targeted antihypertensive therapy induces regression of excess myocardial mass, though long-term clinical trial evidence remains necessary to quantify clinical event reductions.

Messerli et al. (1993) studied this question.

View Full Paper

Ask AI

Bookmark